A new federal enforcement discretion policy allowing qualifying 503A compounding pharmacies to compound six previously restricted peptides is raising questions about state-level oversight and regulatory compliance. The U.S. Department of Health and Human Services (HHS) has announced that it will refrain from taking certain enforcement actions against pharmacies and physicians that meet specified requirements. However, the policy does not override state pharmacy laws or prevent state regulators from pursuing enforcement actions. Compounding pharmacies must navigate varying state requirements while complying with federal conditions governing ingredient sourcing, quality standards, adverse event reporting, and patient-specific prescriptions.
In an article by Law360, Edgar J. Asebey emphasized the uncertainty surrounding how individual states will respond to the federal policy. “Some states may adopt the HHS framework, ignore it or reject it,” Edgar explained, warning that state pharmacy boards could still discipline pharmacists or physicians for dispensing or prescribing unapproved drugs, even where the FDA does not take action. He advised compounders to confirm their state board of pharmacy’s position before proceeding under the new policy. Looking ahead, the policy could represent a significant shift in the peptide market, opening the door to “‘mainstreaming’ certain peptides.”
